Teva Expands Samsung Bioepis Collaboration With ETICOVO, Infliximab-Abda Deal; Upfront Payment Over 3 Years, Launch And Sales Milestones Possible, Profits Shared
Benzinga Newsdesk 1 day ago
News
Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027Collaboration combines Samsung Bioepis’ biosimilar expertise with Teva’s commercial
- Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027
- Collaboration combines Samsung Bioepis’ biosimilar expertise with Teva’s commercial capabilities
- Agreement expands collaboration with Samsung Bioepis, strengthening Teva’s generics powerhouse and biosimilars portfolio as part of its Pivot to Growth strategy